Results for tag: "Sunitinib Malate"

Sunitinib malate, marketed under the brand name Sutent among others, falls within the category of targeted oncology drugs, specifically acting as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its market presence is dictated by its efficacy in treating various types of cancer, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNETs). Sunitinib malate operates by blocking multiple molecular targets implicated in the growth, proliferation, and spread of cancer cells. Due to its targeted approach, it represents an alternative to conventional chemotherapy, offering a different side effect profile and method of action. Its utility in the field of oncology continues to be explored with ongoing research assessing its potential application in other malignancies. Several pharmaceutical and biotechnology companies have a stake in the market for sunitinib malate. Pfizer Inc. is the most prominent as the originator and manufacturer of Sutent, the landmark brand of sunitinib. Other companies may be involved in the distribution or production of generic forms of the drug. These include but are not limited to Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V. This market is subject to the stringent regulations and patent laws related to novel oncology therapies, which influence the competitive landscape as well as the availability of generic versions. Show Less Read more